A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia

Outcomes for older adults with acute myelogenous leukemia (AML) are poor due to both disease and host-related factors. In this phase 2 study, we tested the oral farnesyltransferase inhibitor tipifarnib in 158 older adults with previously untreated, poor-risk AML. The median age was 74 years, and a m...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Lancet, Jeffrey E., Gojo, Ivana, Gotlib, Jason, Feldman, Eric J., Greer, Jacqueline, Liesveld, Jane L., Bruzek, Laura M., Morris, Lawrence, Park, Youn, Adjei, Alex A., Kaufmann, Scott H., Garrett-Mayer, Elizabeth, Greenberg, Peter L., Wright, John J., Karp, Judith E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2007
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC1794070/
https://ncbi.nlm.nih.gov/pubmed/17082323
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2006-04-014357
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak